COMBINATION DRUG TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS

肌萎缩侧索硬化症的联合药物试验

• 批准号: 7605822
• 负责人: RUP TANDAN
• 金额: $ 1.45万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605822
• 关键词: Amyotrophic Lateral Sclerosis; Computer Retrieval of Information on Scientific Projects Database; Creatine; Drug Combinations; Funding; Grant; Human; Individual; Institution; Lead; Minocycline; Nerve Degeneration; Neurodegenerative Disorders; Neurons; Phase; Research; Research Personnel; Resources; Source; Superoxide Dismutase; United States National Institutes of Health; celecoxib; design; mouse model

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is part of our research into safe and effective neuroprotective therapies for amyotrophic lateral sclerosis (ALS), a progressive and incurable neurodegenerative disorder. Multiple mechanisms involved in neurodegeneration lead to neuronal demise in ALS. This proposal has several unique features. First, it will compare in human ALS the neuroprotective potential of two combinations of agents that influence different mechanisms of neurodegeneration. The combinations of minocycline/creatine and celecoxib/creatine have shown additive effects in the SOD mouse model of ALS, reducing neurodegeneration and prolonging survival more than individual agents alone. Second, it will use an important new phase II selection trial design to determine which combination is superior.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该项目是我们对肌萎缩性侧索硬化症（ALS）的安全有效神经保护疗法的研究的一部分，肌萎缩性疗法是一种进行性和无法治愈的神经退行性疾病。涉及神经退行性的多种机制导致ALS的神经元灭亡。该建议具有几个独特的功能。首先，它将在人类ALS中比较两种影响神经退行性机制不同机制的药物组合的神经保护潜力。在ALS的SOD小鼠模型中，米诺环素/肌酸和塞来氧化肌酸/肌酸的组合表现出了添加效应，比单独单独的药物降低了神经变性和延长生存率。其次，它将使用重要的新型II期选择试验设计来确定哪种组合优越。